Hi-TIDe : Immune monitoring and discovery

| Research interest | Research group projects | Selected Publications
 

DO_Pls-0439.jpg

Alexandre HARARI
Privat-docent | Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Head of clinical Immune-monitoring core
Scientific deputy director of Center of experimental therapeutics

Phone +41 79 5567708
Email Alexandre.harari@chuv.ch

Ludwig.jpg (Print)

 

 

Research interest

Our objective is to better understand two distinct components of the dynamic between tumors and T cells: what are tumor rejection antigens and what are the T-cell features associated with better efficacy. These are key questions in the development of novel personalized therapies. 

Research group projects

  • To develop a high-throughput platform to interrogate patients' immunity against private antigens and to identify highly-functional T cells (and TCRs) for ACT.
     
  • To identify biological and clinical correlates of the functional heterogeneity of neo-epitope-specific CD8 T cells.
     
  • To develop new tools to improve personalized cancer immunotherapy.

Selected Publications

  • J. L. Tanyi, S. Bobisse, E. Ophir, S. Tuyaerts, A. Roberti, R. Genolet, P. Baumgartner, B. J. Stevenson, C. Iseli, D. Dangaj, B. Czerniecki, A. Semilietof, J. Racle, A. Michel, I. Xenarios, C. Chiang, D. S. Monos, D. A. Torigian, H. L. Nisenbaum, O. Michielin, C. H. June, B. L. Levine, D. J Powel Jr, D. Gfeller, R. Mick, U. Dafni, V. Zoete, A. Harari, G. Coukos, L. E. Kandalaft. Personalized Cancer Vaccine Effectively Mobilizes Antitumor Immunity in Ovarian Cancer. Science Transl Med (2018).

  • S. Bobisse, R. Genolet, A. Roberti, J. L. Tanyi, J. Racle, B. J. Stevenson, C. Iseli, A. Michel, MA Le Bitoux, P. Guillaume, J. Schmidt, V. Bianchi, D. Dangaj, C. Fenwick, L. Derré, I. Xenarios, O. Michielin, P. Romero, D. S. Monos, V. Zoete, D. Gfeller, L. E. Kandalaft, G. Coukos, A. Harari. Sensitive and Frequent Identification of High Avidity Neo-epitope Specific CD8+ T-cells in Immunotherapy-naïve Ovarian Cancer. Nature Communications. (2018).

  • S. Bobisse, P. G. Foukas, G. Coukos & A. Harari. Neoantigen-Based Cancer Immunotherapy. Annals of Translational Medicine. (2016).

  • H. Maecker & A. Harari. Immune Monitoring Technology Primer:  Flow and Mass Cytometry. J Immunother Cancer. (2015).

  • E. Romano, O. Michielin, V. Voelter, J. Laurent, H. Bichat, A. Stravodimou, P. Romero, D. E. Speiser, F. Triebel, S. Leyvraz & A. Harari. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med. (2014).

 

Group members

  • Marion ARNAUD
    PhD student
  • Aymeric AUGER
    Technician
  • Petra BAUMGARTNER
    Senior scientist
  • Valentina BIANCHI
    Postdoctoral fellow
  • Sara BOBISSE
    Senior scientist
  • Julien CESBRON
    Technician
  • Raphael GENOLET
    Senior scientist
  • Philippe GUILLAUME
    Senior scientist
  • Marie-Aude LE BITOUX
    Technician
  • Morgane MAGNIN
    PhD student
  • Alexandra MICHEL
    Technician
  • Blanca NAVARRO
    MD fellow and PhD student
  • Tu NGUYEN
    MD fellow
  • Lise QUEIROZ
    Technician
  • Julien SCHMIDT
    Senior scientist
  • Anne-Christine THIERRY
    Technician
Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
ludwig_cancer_research-logo.svg universite_de_lausanne-logo.svg chuv-logo.svg